Menu Search

Gimv invests in Belgian biotech company Camel-IDS, to support its unique radio-immunotherapy platform

Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals today announced the completion of a series-A financing round, whereby the company secured funding of EUR 37 million. Gimv, who leads this round together with V-Bio Ventures, invests EUR 6 million.